ClinicalTrials.gg
Not yet recruitingNCT06338826BI-LIGHTUpdated Feb 5, 2025

Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses

A Phase 2 interventional study of TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI and Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR) in HIV Infections and HBV Coinfection, sponsored by ANRS, Emerging Infectious Diseases. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-05.

Sponsored by ANRS, Emerging Infectious Diseases · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 98 studies testing tenofovir in HIV Infections — 1 open to participants now, 3 under way, 1 of them phase 3. Tenofovir · HIV Infections.

Planned enrollment
38th of 94
140 · median 99
Started
2025
the only one that year
Phase 2
22 of 98
1 open now
Registered
97th of 98
by date
Lead sponsor
3 of 98
ANRS, Emerging Infectious Diseases

Among the 98 studies testing tenofovir in HIV Infections, this one is the 38th largest by planned enrollment of the 94 interventional ones that give a count, is the only one that started in 2025, is one of 22 in phase 2, and was the 97th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 98 studies testing tenofovir in HIV Infections is open now.

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing tenofovir in HIV Infections, or all of them as a file.
02

Study summary

The main objective of this study is to evaluate at 96 weeks the safety with respect to hepatitis B control of 2 treatment reduction strategies for patients with previously controlled HIV-HBV co-infection on continuous triple therapy

03

Conditions studied

  • HIV Infections
  • HBV Coinfection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. -1- co-infection (positive HIV-1 serology associated with 2 positive HBsAg serologies within more than 6 months);
  2. Age ≥ 18 years
  3. Fibroscan less than 6 months \< 9kPa
  4. Current daily antiretroviral tritherapy not modified for ≥ 12 months must including tenofovir disoproxil fumarate (TDF) 245mg or tenofovir alafenamide fumarate (TAF -25mg) associated to lamivudine (3TC - 300mg) or emtricitabine (FTC - 200mg) and a NNRTI or PI/r or INSTI to choose from

    • NNRTI = efavirenz, rilpivirine, etravirine, doravirine
    • PI/r = atazanavir/r ou darunavir/r
    • INSTI = bictegravir, dolutegravir, elvitegravir/cobicistat, raltegravir;
  5. Absence of documented HBV and HIV genotypic resistance compromising virologic control of any of the maintenance strategies. Patients with no genotypic history may be included);
  6. HIV CV \< 50cp/ml for ≥ 2 years (only 1 annual blip allowed if HIV CV \< 200cp/ml and previous and subsequent viral loads are undetectable);
  7. HBV CV \< 10 IU/ml for ≥ 2 years (only 1 annual blip allowed if HBV CV \< 200IU/ml and if previous and subsequent viral loads are undetectable);
  8. Have ≥ 3 available measurements of HIV CV \< 50cp/ml and HBV CV \< 10 IU/mL over the past 24 months (including that of pre-inclusion);
  9. CD4 lymphocytes > 250/mm3 at pre-inclusion;
  10. \< 3N at pre-inclusion;
  11. For women of , negative pregnancy test and commitment to use effective throughout the trial;
  12. Person affiliated with or benefiting from a social security system;
  13. Free, informed, written consent, signed by the person and the investigator at the latest on the day of inclusion and before any examination carried out as part of the study (article L1122-1-1 of the Public Health Code)

Exclusion criteria

Exclusion Criteria:

  1. -2 infection;
  2. HIV and/or genotype not compatible with dual therapy DTG-3TC or DRVr-3TC;
  3. HBeAg+;
  4. Fibrosis history at stage F3-F4 in pre-therapy evaluated by PBH, fibrotest and/or fibroscan with a value of Elastometry ≥ 9kPa;
  5. Chronic active viral (HCV RNA positive);
  6. Delta co-infection;
  7. Alcohol consumption > 14 units/week for women and 21 units/week for men;
  8. Current treatment with chemo- or immunotherapy (including interferon or interleukins);
  9. Active opportunistic infection or acute treatment for opportunistic infection;
  10. Any condition (drug use, neurological, neuropsychiatric, etc.) that, in the judgment of the investigator, may compromise patient compliance and adherence to the protocol;
  11. Pregnant or breastfeeding woman or refusal of ;
  12. Major incapacity, legal protection, guardianship or curatorship
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
140 participants (estimated)

Study arms

  • No intervention
    Arm 1

    - Arm 1 (reference arm): Continuation of continuous (7 days/week) triple antiviral therapy including TDF or TAF

  • Experimental
    Arm 2 (T4):

    - Arm 2 (T4): Relief from previous triple antiviral therapy (containing TDF or TAF) on 4 out of 7 consecutive days

    Drug: TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI

  • Experimental
    Arm 3 (B7)

    Switch from prior triple antiviral therapy (containing TDF or TAF) to continuous dual therapy without TDF or TAF but including 3TC in combination with Dolutegravir (DTG) or ritonavir-boosted Darunavir (rDVR

    Drug: Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)

Interventions

  • DrugTDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI

    Drug page: TenofovirStudies of TenofovirTenofovir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The study will include patients under current daily antiretroviral tritherapy not modified for ≥ 12 months must including tenofovir disoproxil fumarate (TDF) 245mg or tenofovir alafenamide fumarate (TAF -25mg) associated to lamivudine (3TC - 300mg) or emtricitabine (FTC - 200mg) and a NNRTI or PI/r or INSTI to choose from * NNRTI = efavirenz, rilpivirine, etravirine, doravirine * PI/r = atazanavir/r ou darunavir/r * INSTI = bictegravir, dolutegravir, elvitegravir/cobicistat, raltegravir

  • DrugDual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)

    dual therapy without TDF or TAF but including 3TC in combination with Dolutegravir (DTG) or ritonavir-boosted Darunavir (rDVR

06

What researchers measure

Primary outcomes

  1. The proportion of participants with HBV virological failure at 96 weeks.

    HBV virologoical failure is defined by 2 successive varial load ≥ 10UI/ml

    Time frame: 96 weeks

Secondary outcomes

  1. • HBV virological success rate at 48 weeks

    HBV virological success is defined by a viral load ≤10 UI/ml

    Time frame: at Week 48

  2. • HIV virological success rate at 48 and 96 weeks

    HIV virological success is defined by a viral load ≤ 50 cp/ml

    Time frame: At week 48 and week 96

  3. • Time to virological failure (rebound HBV and/or HIV viral load)

    Time frame: between Week 0 and Week96

  4. • The rate of participants with at least one HBV viral load blip until W48 and until W96

    a blip is defined by a HBV viral load \>10UI/mL followed by a control value ≤ 10UIml

    Time frame: At week 48 and week 96

  5. • Selection of HBV resistance mutations at the time of virological failure

    Time frame: between Week 0 and Week 96

  6. • Incidence of grade 3 or higher adverse events of grade 3 or higher, incidence of adverse events and incidence of strategy discontinuation of the strategy at W48 and W96

    Time frame: At week 48 and week 96

  7. • Evolution of CD4 from W0 to W48 and W96

    Time frame: Week 0 to Week 48 and week 96

  8. • Evolution of total cholesterol from W0 to W48 and W96

    Time frame: from Week 0 to Week 48 and Week 96

  9. • Evaluation of the adherence by self-reported questionnaire

    without analysis scale

    Time frame: at Week 0, Week 12, Week 24, Week 48, Week 72 and Week 96

  10. • Evaluation of quality of life using the Pro-Qol self-questionnaire

    without analysis scale

    Time frame: at Week 0, Week 12, Week 24, Week 48, Week 72 and Week 96

  11. Evolution of CD8 T lymphocytes from W0 to W48 and W96

    Time frame: Week 0 to Week 48 and week 96

  12. Evolution of the CD4/CD8 ratio from W0 to W48 and W96

    Time frame: Week 0 to Week 48 and week 96

  13. Evolution of LDL-c from W0 to W48 and W96

    Time frame: from Week 0 to Week 48 and Week 96

  14. Evolution of HDL-c from W0 to W48 and W96

    Time frame: from Week 0 to Week 48 and Week 96

  15. Evolution of triglycerides from W0 to W48 and W96

    Time frame: from Week 0 to Week 48 and Week 96

  16. Evolution of fasting blood sugar from W0 to W48 and W96

    Time frame: from Week 0 to Week 48 and Week 96

  17. HBV virological success rate at 96 weeks between arms

    HBV virological success is defined by a viral load ≤10 UI/ml

    Time frame: at Week 96

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Sep 2027, 31 months later.

Of 64 non-industry phase 2 interventional studies under HIV Infections, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 74. This study's planned 31 months is below that.

Counting every sponsor, half of 98 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Apr 1, 2024
StartEst.
Feb 1, 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Feb 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06338826
Responsible party
Sponsor
First posted
Apr 1, 2024
Start date
Feb 1, 2025 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Feb 5, 2025

Study contacts

Fatoumata COULIBALY
Contact
fatoumata.coulibaly@anrs.fr
0144236110 ext. +33
Julie Bottero
principal investigator · Bicetre Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion